Dr Neeraj Narula and colleagues assessed the tolerability, and efficacy of high-dose vitamin D3 in patients with Crohn’s disease (CD).
The research team performed a randomized, double-blind placebo-controlled trial of high-dose vitamin D3 at 10,000 IU daily compared to 1000 IU daily for 12 months in patients with CD in remission.
The team's primary outcome was change in serum 25-hydroxy-vitamin D levels.
The researchers' secondary outcomes included clinical relapse rates and changes in mood scores.
|High-dose vitamin D3 at 10,000 IU daily improved 25-hydroxy-vitamin D levels |
|Digestive Diseases & Sciences|
High-dose vitamin D3 at 10,000 IU daily significantly improved 25-hydroxy-vitamin D levels from a mean of 73.5 nmol/L.
The team found that the rate of relapse was not significantly different between patients receiving low- and high-dose vitamin D3.
In per-protocol analysis, the researchers observed that the clinical relapse of Crohn’s disease was less frequently observed in patients receiving a high dose compared to those receiving a low dose of 1000 IU daily.
The research team noted that improvement in anxiety and depression scores, and a good safety profile were observed in both groups treated with vitamin D3.
Dr Narula's team concludes, "Oral supplementation with high-dose vitamin D3 at 10,000 IU daily significantly improved serum 25-hydroxy-vitamin D levels."
"Rates of clinical relapse were similar between both groups."
"Larger studies using high-dose vitamin D3 for treatment of inflammatory bowel diseases are warranted."